Compare Stocks → This Apple-like Innovator is Revolutionizing Healthcare (From Wall Street Star) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ADAPNASDAQ:AURANASDAQ:OPTNASDAQ:OYST Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADAPAdaptimmune Therapeutics$1.10-3.9%$1.39$0.42▼$2.05$1.09B2.391.77 million shs541,435 shsAURAAura Biosciences$7.13-1.2%$8.03$5.99▼$13.50$352.94M0.36169,199 shs41,297 shsOPTOpthea$3.42+1.8%$3.54$1.60▼$4.42$199.73M1.1923,513 shs1,031 shsOYSTOyster Point Pharma$11.17$11.15$3.46▼$19.00$299.85M1.31212,171 shs330 shsBeginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADAPAdaptimmune Therapeutics+12.87%+10.68%-20.83%+59.44%-17.39%AURAAura Biosciences+1.83%-0.55%-14.25%-3.48%-18.97%OPTOpthea-0.59%-5.08%-11.11%+27.76%-3.59%OYSTOyster Point Pharma0.00%0.00%0.00%0.00%0.00%The A.I. story nobody is telling you (Read ASAP) (Ad)There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...Click here to see Louis' new video for yourself.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADAPAdaptimmune Therapeutics1.0708 of 5 stars2.53.00.00.02.50.80.6AURAAura Biosciences1.4581 of 5 stars3.50.00.00.02.91.70.6OPTOpthea1.7284 of 5 stars3.54.00.00.00.60.80.6OYSTOyster Point PharmaN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADAPAdaptimmune Therapeutics1.00Sell$2.50128.31% UpsideAURAAura Biosciences3.00Buy$21.00194.53% UpsideOPTOpthea3.00Buy$14.00309.36% UpsideOYSTOyster Point PharmaN/AN/AN/AN/ACurrent Analyst RatingsSales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADAPAdaptimmune Therapeutics$60.28M18.06N/AN/A$0.04 per share27.38AURAAura BiosciencesN/AN/AN/AN/A$4.58 per shareN/AOPTOpthea$110K1,815.71N/AN/A($0.10) per share-34.20OYSTOyster Point Pharma$24.54M12.22N/AN/A$3.80 per share2.94Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADAPAdaptimmune Therapeutics-$113.87M-$0.55N/AN/AN/A-188.90%-155.39%-43.42%5/10/2024 (Estimated)AURAAura Biosciences-$76.41M-$1.92N/AN/AN/AN/A-42.20%-36.66%5/9/2024 (Estimated)OPTOpthea-$142.52MN/A0.00N/AN/AN/AN/AN/AN/AOYSTOyster Point Pharma-$100.66M-$6.65N/AN/AN/A-901.99%-490.33%-108.29%N/ALatest ADAP, OYST, OPT, and AURA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/27/2024Q4 2023AURAAura Biosciences-$0.39-$0.50-$0.11-$0.50N/AN/A3/6/2024Q4 2023ADAPAdaptimmune Therapeutics-$0.12-$0.24-$0.12-$0.24$4.80 million$0.23 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADAPAdaptimmune TherapeuticsN/AN/AN/AN/AN/AAURAAura BiosciencesN/AN/AN/AN/AN/AOPTOptheaN/AN/AN/AN/AN/AOYSTOyster Point PharmaN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADAPAdaptimmune TherapeuticsN/A2.852.85AURAAura BiosciencesN/A18.7618.76OPTOptheaN/AN/AN/AOYSTOyster Point Pharma8.493.353.11OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADAPAdaptimmune Therapeutics31.37%AURAAura Biosciences96.75%OPTOpthea55.95%OYSTOyster Point Pharma96.70%Insider OwnershipCompanyInsider OwnershipADAPAdaptimmune Therapeutics12.44%AURAAura Biosciences5.90%OPTOpthea3.20%OYSTOyster Point Pharma17.90%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableADAPAdaptimmune Therapeutics449994.21 million870.53 millionOptionableAURAAura Biosciences8849.50 million46.58 millionNot OptionableOPTOpthea2458.40 million56.53 millionNot OptionableOYSTOyster Point Pharma30326.84 million22.04 millionNot OptionableADAP, OYST, OPT, and AURA HeadlinesSourceHeadlineAs biotech vacancies hit 20%, oversupply of space could crunch crossover developersbizjournals.com - April 19 at 8:47 PMCalusa Waterkeeper talks building vertical oyster gardenspineisland-eagle.com - April 18 at 8:35 AMDry Eye Syndrome Market Poised to Reach USD 7,940 Million by 2032: Unveiling Growth Factorspharmiweb.com - April 17 at 10:12 AMThe 25 Best Restaurants in Boston Right Nownytimes.com - April 15 at 9:28 AMDrug Take Back Day: Free, responsible disposal systemtownsquaredelaware.com - April 14 at 2:41 PMOyster farmers dressed for workrrecord.com - April 3 at 6:27 PMFlood warning issued for Cumberland County until early Saturday morningpennlive.com - April 3 at 8:26 AMPortions of Mobile Bay reopen for oyster harvestingmsn.com - April 3 at 2:19 AM8th annual Gulf Coast Oyster Cook-Off kicks offwxxv25.com - March 29 at 2:56 PMThe world is indeed your oyster at the beach in all kinds of waysmsn.com - March 29 at 8:33 AMThe 10 Best Oyster Restaurants In Atlantamsn.com - March 28 at 8:22 PMBroad Street Oyster Co.’s Legendary Lobster Rolls Land at Ghirardelli Square Tomorrowmsn.com - March 28 at 8:22 PMWhat’s the Best Substitute for Oyster Sauce? We Have 10 Tasty Swapsmsn.com - March 24 at 7:41 PMSanctuary Changes Inching Amidst Astounding Oyster Effortstalbotspy.org - March 13 at 3:09 PMMaryland’s Oyster Sanctuaries Show Promising Signs by Joe Zimmermanntalbotspy.org - March 12 at 1:47 PMSophomore Bussiere shines in net for Oyster River/Portsmouth in state championship losssports.yahoo.com - March 9 at 5:30 PMAww shucks!!! Oyster recycling program reaches major milestoneyahoo.com - March 6 at 10:34 PMBiotechnology Licensing Deals Analysis Reveals Key Trends and Major Agreements from 2019-2024uk.finance.yahoo.com - March 5 at 12:56 PMOyster restoration project focuses on increasing diversity in marine scienceswbur.org - March 4 at 3:59 PMQ4 2023 Viatris Inc Earnings Calluk.finance.yahoo.com - February 28 at 11:13 PMPopular oyster bar reopens after fire in Annapoliswmar2news.com - February 28 at 11:13 PMOyster River School Board candidate John Colwellnews.yahoo.com - February 22 at 6:18 AMOyster Point Pharma Inc.thestreet.com - February 18 at 1:41 PMNorthern California’s oyster capital is a hidden gemnationalgeographic.com - February 16 at 2:39 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines3 Stocks With Unusual Call Option ActivityMarch 26, 2024 1:10 PMView 3 Stocks With Unusual Call Option ActivityBest Bear Market Funds: Top 3 Investment Options to ConsiderMarch 27, 2024 10:58 AMView Best Bear Market Funds: Top 3 Investment Options to ConsiderDelta Airline’s Put Option Activity Isn’t Bad NewsMarch 28, 2024 8:55 AMView Delta Airline’s Put Option Activity Isn’t Bad NewsHow and When to Roll Your Options Positions? March 27, 2024 9:32 AMView How and When to Roll Your Options Positions? ASML Fires Warning Shot For Tech InvestorsApril 17, 2024 9:05 AMView ASML Fires Warning Shot For Tech InvestorsAll Headlines Company DescriptionsAdaptimmune TherapeuticsNASDAQ:ADAPAdaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.Aura BiosciencesNASDAQ:AURAAura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.OptheaNASDAQ:OPTOpthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead product candidate is Sozinibercept (OPT 302), a soluble form of vascular endothelial growth factor receptor-3 VEGFR-3, currently under Phase 3 clinical development as a novel therapy for wet age-related macular degeneration and diabetic macular edema. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.Oyster Point PharmaNASDAQ:OYSTOyster Point Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ophthalmic diseases in the United States. The company's product candidate is TYRVAYA, a nicotinic acetylcholine receptor agonist for the treatment of signs and symptoms of dry eye disease. It is also developing TYRVAYA that is in Phase II clinical trial for the treatment of for neurotrophic keratopathy. The company was incorporated in 2015 and is headquartered in Princeton, New Jersey. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.